Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07219849
PHASE2

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Sponsor: Alixer Nexgen Therapeutics Limited

View on ClinicalTrials.gov

Summary

This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.

Official title: A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber/EEC

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

164

Start Date

2025-10-17

Completion Date

2026-04

Last Updated

2025-10-22

Healthy Volunteers

Yes

Interventions

DRUG

ALDP001 Nasal Spray

Experimental Arm

DRUG

Placebo Nasal spray

Controlled arm

Locations (1)

Cliantha Research

Mississauga, Ontario, Canada